MARKET

DXR

DXR

DAXOR CORP
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.25
-0.75
-5.77%
Closed 16:00 05/17 EDT
OPEN
12.22
PREV CLOSE
13.00
HIGH
12.25
LOW
12.22
VOLUME
408
TURNOVER
4.61K
52 WEEK HIGH
15.46
52 WEEK LOW
8.58
MARKET CAP
49.41M
P/E (TTM)
10.43
1D
5D
1M
3M
1Y
5Y
Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Conference
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will present at the H.C. Wainwright Global Life Investment Hybrid...
GlobeNewswire · 5d ago
Daxor Highlights New Data Validating Benefits Of Co.'s BVA-100 Blood Test For Advanced Heart Failure Patients
Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces new data validating the benefits of the Company’s BVA-100 blood test (BVA) in improving survival for advanced
Benzinga · 05/02 12:18
New Data Validates Blood Volume Analysis Guided-Care, Improves Survival in Patients with Advanced Heart Failure Supported with Left Ventricular Assist Device
Study Presented at the International Society for Heart and Lung Transplant 42nd Annual Meeting and Scientific Sessions 2022 Oak Ridge, TN, May 02, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement techn...
GlobeNewswire · 05/02 12:00
Daxor blood volume test BVA-100 shows accuracy for heart condition in new study
Daxor (NASDAQ:DXR) said new data for its BVA-100 test showed the system was uniquely able to measure the intravascular congestion of heart failure patients, a key metric that is targeted
Seekingalpha · 04/06 13:35
New Study from Duke Heart Demonstrates the Unique Accuracy and Utility of Daxor’s Blood Volume Diagnostic (BVA-100®) for Improving Worsening Heart Failure
Study Presented at the 71st Annual American College of Cardiology Meeting Oak Ridge, TN, April 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from Duke Heart ...
GlobeNewswire · 04/06 12:00
Daxor Corporation to Participate in the Maxim Group 2022 Virtual Growth Conference
Oak Ridge, TN, March 23, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that President and CEO Michael Feldschuh will present at Maxim Group 2022 Virtual Growth Conference to be...
GlobeNewswire · 03/23 12:00
Daxor reports FY results
Daxor press release (NASDAQ:DXR): FY NAV of $5.24 per share versus $3.89 in FY 2020.
Seekingalpha · 03/01 14:15
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
Oak Ridge, TN, March 01, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR...
GlobeNewswire · 03/01 14:00
More
No Data
Learn about the latest financial forecast of DXR. Analyze the recent business situations of DAXOR CORP through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average DXR stock price target is 22.50 with a high estimate of 23.00 and a low estimate of 22.00.
High23.00
Average22.50
Low22.00
Current 12.25
EPS
Actual
Estimate
-0.340.230.811.38
2019/12
2020/06
2020/12
2021/06
2021/12
Institutional Holdings
Institutions: 8
Institutional Holdings: 160.18K
% Owned: 3.97%
Shares Outstanding: 4.03M
TypeInstitutionsShares
Increased
1
430
New
0
0
Decreased
2
38.53K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Closed End Funds
+0.70%
Collective Investments
+0.70%
Key Executives
Chairman/President/Chief Executive Officer/Director
Michael Feldschuh
Chief Financial Officer
Robert Michel
Chief Scientific Officer/Director
Jonathan Feldschuh
Independent Director
Henry Cremisi
Independent Director
Caleb Desrosiers
Independent Director
Edward Feuer
Independent Director
Joy Goudie
Independent Director
James Lombard
No Data
No Data
About DXR
Daxor Corporation is a diversified, closed-end management investment company. The Company’s investment objectives are capital preservation, maintaining returns on capital with a high degree of safety and generating income from dividends and option sales to help offset operating losses from the Company’s operating division. The Company intends to maintain a diversified securities portfolio comprised primarily of electric utility company common and preferred stocks. The Company seeks to maintain a minimum of 80% of its portfolio in equity securities of utility companies.

Webull offers kinds of Daxor Corporation stock information, including NASDAQ:DXR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DXR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DXR stock methods without spending real money on the virtual paper trading platform.